6-0-(2-Tetradecylhexadecanoyl)-N-acetylmuramyl-L-alanyl-D-isoglutamine (B30-MDP) and 6-0-(3-hydroxy-2-docosylhexacosanoyl)-MDP (BH48-MDP) were examined for immunopotentiating activity in stimulating the primary immune responses of guinea pigs to ovalbumin and for adverse reactions at the injection site and in the regional lymph nodes when administered in combination with several nonirritating vehicles. B30-MDP was found to potently stimulate both humoral and cellular immune responses, the latter by induction of delayed-type hypersensitivity, irrespective of the administration vehicle examined (liposomes, a squalene in water emulsion, Intralipid, phosphate-buffered saline, and Nikkol HCO-60 glucose solution), although the minimum effective dose was dependent on the vehicle used. Reactions in the footpad receiving the injection were negligible. Noticeable local reaction consisted of swelling of the lymph nodes in the region of the injection, but the swelling was only noted with higher doses and subsided 3 to 4 weeks after immunization, unlike the persistent swelling caused by the administration of water-in-mineral oil emulsions with or without B30-MDP. BH48-MDP and its L-serine analog, BH48-MDP(L-Ser), which has L-serine in place of L-alanine in MDP, in combination with the squalene-in-water emulsion, also intensely stimulated both cellular and humoral antiovalbumin immune responses, but the effects of these compounds seemed to be influenced to a greater degree by the vehicles than by B30-MDP. Thus, B30-MDP was chosen from a series of a 6-0-acyl derivatives of MDP as the most promising candidate for possible application in practical vaccines.
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In an earlier study (6) , we compared the immunopotentiating ability of 13 6-0-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine (6-0-acyl-MDP) to stimulate primary immune responses (humoral and cellular) of guinea pigs to ovalbumin when administered in combination with various vehicles. Among them, 6-0-(2-tetradecylhexadecanoyl)-MDP (B30-MDP) and, to a lesser extent, 6-0-(3-hydroxy-2-docosylhexacosanoyl)-MDP (BH48-MDP) were found to exert strong adjuvant activity in both the induction of delayed-type hypersensitivity and the stimulation of circulating precipitating antibody levels when combined with nonirritating vehicles such as liposomes, squalene-in-water emulsion, and phosphate-buffered saline. These two compounds have a-branched higher fatty acid groups at the 6-position of the muramic acid residue and, when administered intravenously, have no detectable pyrogenicity, which is one of the harmful bioactivities of the parent molecule, MDP.
Thus, we focused our attention on B30-MDP and BH48-MDP (or its L-serine analog) and investigated their effects on primary immune responses, both humoral and cell mediated, and the local injurious reactions caused when it was administered to guinea pigs at graded doses with ovalbumin in combination with several vehicles. procedures for the synthesis of B30-MDP, BH48-MDP, and BH48-MDP(L-Ser) have been described in the preceding paper (6) .
Assay for immunoadjuvant activities. The assay methods for immunoadjuvant activity described in the preceding paper (6) were followed, except that the maximum dose of test adjuvants examined was adjusted to 202 nmol (equivalent to 100 ,ug of MDP); i.e., 188, 243, and 246 ,ug of B30-MDP, BH48-MDP, and BH48-MDP(L-Ser), respectively, to simplify the comparison and to conserve test compounds because of their limited availability.
Vehicles used for the administration of test adjuvants with antigen. In addition to the vehicles used in the preceding study (6) , the following two vehicles were examined for their ability to support the adjuvanticity of test adjuvants. (i) Intralipid, 10%. This fat emulsion, used clinically to give calories and essential fatty acids to patients, was purchased from Ohtsuka Pharmaceutical Co., Tokyo, Japan. It consisted of 10% soybean oil, 1.2% egg yolk phospholipids, 2.5% glycerol, and water; the pH was adjusted to between 6.5 and 8.5 with sodium hydroxide.
(ii) Nikkol HCO-60 glucose solution, 5%. This vehicle was prepared by dissolving 5 g of Nikkol HCO-60, a nonionic surfactant of polyoxyethylene (60 [condensation degree of ethylene oxide]) hydrogenated caster oil derivative for medical use (Nikko Chemical Co., Tokyo), in 50 ml of warmed 1/30 M phosphate buffer, pH 7.5, and then adding 4 g of glucose and adjusting the total volume to 100 ml. Nikkol HCO-60 was used to increase the dispersion of B30-MDP, which does not give a clear solution in 1/75 M phosphatebuffered saline (PBS), pH 7.0. Measurement of swelling at the injection site and regional lymph nodes. Swelling of the footpad caused by immunogen injection was measured by determining the ratio of the cross-section of the injected footpad to that of the control. Swelling of inguinal and popliteal lymph nodes (regional lymph nodes) of the hind foot injected was scored as 0.5, 1, or 2 as described in the legend to Fig. 4 , and the values were added for each individual animal.
Statistical significance. The difference in results between each test and the respective control was examined by Student's t test for most of the assays. (Fig. 1) . Production of circulating antibodies was similarly stimulated by B30-MDP administered with the above vehicles (Fig. 2) . Ribi-type squalene-in-water emulsion and Intralipid as vehicles were especially effective for enhancement of serum antibody production. MDP (100 ,ug, 202 nmol) was not a good adjuvant with Intralipid or Nikkol HCO-60 glucose solution (data not shown). Though the above noninritating vehicles were satisfactorily effective in supporting the adjuvanticity of B30-MDP, water-in-mineral oil (w/o) emulsion was considered the most effective vehicle even in combination with B30-MDP, because the effective dose of B30-MDP with this vehicle was considerably lower than that in combination with other vehicles, although a minimum effective dose could not be determined in the present assays.
The reactions at the injection site and the regional (inguinal and popliteal) lymph nodes at 20 days after immunization with the above dose-response experiments are shown in Fig. 3 . Administration with w/o emulsions containing 0.8 ,ug of B30-MDP caused severe swelling of the inoculation site, but swelling of the injection site with B30-MDP (up to 188 pug per animal) with the other vehicles was far less (Fig. 3A) . Swelling of the regional lymph nodes was not induced by B30-MDP in combination with liposomes, Intralipid, PBS, or Nikkol IJCO-60 glucose solution except at the highest dose used (188 ,ug). Administration of B30-MDP with PBS or squalene-in-water emulsions caused detectable lymph node swelling at higher dosages, but the swelling caused by lower doses was considerably less than that induced by use of w/o emulsions as a vehicle (Fig. 3B) . Figure 4 shows the time course of reactions at the injection site and the regional lymph nodes of guinea pigs receiving the footpad injection of B30-MDP with ovalbumin. At the injection site, no remarkable reactions with B30-MDP and ovalbumin in vehicles other than w/o emulsion were observed during the 4-week observation period. Swelling of the regional lymph nodes, on the other hand, was sometimes considerable for 1 to 2 weeks after the injection, but tended to subside rapidly thereafter. In a control experiment, w/o emulsions containing 1 mg of ovalbumin but no test adjuvant induced significant swelling of the injected site and the regional lymph nodes; swelling in the latter tended to increase during the observation period.
The adjuvanticity of B30-MDP (21 and 63 ,ug) in Intralipid with ovalbumin (1 mg) was examined by intravenous administration in guinea pigs. As shown in Fig. 5 , both induction of delayed-type hypersensitivity and a marked increase of serum antibody production were observed.
(u-) BH48-MDP. A dose-response study was made on the adjuvanticity of BH48-MDP and BH48-MDP (L-Ser), which has the L-serine in place of the L-alanine residue in MDP, by use of Ribi-type squalene-in-water emulsion as a vehicle (Fig. 6) . Both of the test compounds showed a strong ability to induce positive corneal responses and to enhance serum precipitating antibody levels against ovalbumin in guinea pigs without causing significant irritation at either the injection site or the lymph nodes, although the minimum effective dose was not determined in the present assay.
DISCUSSION
In the present study, B30-MDP, which possesses abranched fatty acids with 30 carbon atoms at the 6-position of its muramic acid residue, was shown to exhibit adjuvanticity to stimulate the primary immune responses, both cellular and humoral, against ovalbumin when administered with nonirritating vehicles (liposomes, Ribitype squalene-in-water emulsion, Intralipid, Nikkol HCO-60 glucose solution, and PBS). These vehicles were ineffective or only weakly effective in supporting the adjuvanticity of the parent molecule, MDP. Although the minimum effective dose of B30-MDP varied with the vehicle used, and larger Although BH48-MDP and BH48-MDP(L-Ser) in combination with squalene-in-water emulsions induced positive delayed-type hypersensitivity reactions and increased serum antiovalbumin antibody levels, their use with a wide range of vehicles seemed to be limited; for instance, the effective dose was much larger than that of B30-MDP when used in combination with PBS (data not shown).
Regarding the local reactions caused by footpad injection into guinea pigs, B30-MDP was found to induce no or a tolerable degree of swelling at the injection site when given with the above-mentioned vehicles capable of supporting the inherent adjuvanticity of the compound. Local swelling of lymph nodes near the injection site occurred with higher doses of B30-MDP in all vehicles except Nikkol HCO-60 glucose solution, in which the test compound dissolved. Nevertheless, the swelling caused by B30-MDP in nonirritating vehicles, unlike that with w/o emulsion, subsided 3 to 4 weeks after the immunization. Emori et al. (1) found that B30-MDP in PBS was highly active in induction of massive epithelioid granuloma in guinea pigs, unlike MDP and other 6-0-acyl-MDPs that required w/o emulsion as a vehicle for granuloma formation. Thus, the enlargement of regional lymph nodes caused by B30-MDP seems to be due to induction of granuloma formation, one of the expressions of macrophage activation. On the other hand, the finding that B30-MDP dissolved in Nikkol HCO-60 glucose solution, unlike the same compound finely suspended in PBS, did not cause swelling of lymph nodes or at the injection site suggests that the local reactions observed are partly due to the physicochemical state of the B30-MDP molecule injected.
Another harmful activity of MDP and most of the MDP derivatives is their arthritogenicity. Kohashi et al. reported that SD/NCrj rats receiving 12 daily intravenous injections of 1 mg of B30-MDP per kg dissolved in Nikkol HCO-60 glucose solution or daily subcutaneous administration of 5 mg of B30-MDP per kg in PBS over 2 to 3 weeks developed mild or moderate to severe polyarthritis, respectively (3). Nevertheless, footpad or subcutaneous injection of 1 mg of B30-MDP per kg in Intralipid, PBS, or Nikkol HCO-60 glucose solution did not induce detectable polyarthritis in rats even after repeated daily injections for 1 to 21 days (2). B30-MDP was also shown to cause acute joint inflammation in BALB/c mice by one intravenous injection of 0.1 mg in PBS. However, the inflammation was very mild and com- pletely subsided by day 3 or 4 after the injection (T. Koga, K. Kakimoto, T. Hirofuji, S. Kotani, A. Sumiyoshi, and K. Saisho, Microbiol. Immunol., in press).
Other possibly deleterious bioactivities of MDP and its derivatives in guinea pigs are hemorrhagic and necrotic inflammation at the site of a previous injection of tubercle bacilli suspended in w/o emulsion (4, 5). B30-MDP was inactive in this respect when it was injected as a fine suspension in PBS, although it was an irritant as a solution in Nikkol HCO-60. The phenomenon seems to require a specific set of conditions for its occurrence (3) (4) (5) , but attempts to use some of the MDP analogs in humans should be done cautiously, taking this phenomenon into consideration.
From our findings with this wide range of vehicles, i.e., the small effective dose, the remarkable enhancement of cellular and humoral immunity, and the minimum adverse effects, it was concluded that B30-MDP was the most promising MDP derivative among those assayed for possible application in practical vaccines to potentiate antigenspecific immune. responses.
